Income statement, balance sheet and cash flow statement for the last 1 fiscal years, taken from the XBRL data POMDOCTOR Ltd files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
Revenue
57.2
Cost of revenue
49.7
Gross profit
7.48
Research and development
1.84
Selling and marketing
13.8
General and administrative
8.54
Operating expenses
24.4
Operating income
-17
Interest expense
0.56
Other non-operating income
-1.76
Pre-tax income
-18.7
Income tax
0
Net income to minority interests
-0
Net income
-30.4
EBITDA
-16.9
EPS, basic
-3.14
EPS, diluted
-3.14
Shares, basic (weighted)
9.68
Shares, diluted (weighted)
9.68
Balance sheet
FY2025
Cash and equivalents
1.37
Receivables
2.64
Inventory
1.18
Other current assets
0.51
Total current assets
15
Property, plant and equipment
0.18
Other non-current assets
0.19
Total assets
15.4
Accounts payable
6.41
Accrued liabilities
2.09
Short-term debt
7.58
Total current liabilities
31.2
Lease liabilities
0.19
Total liabilities
84.2
Total debt
11.7
Paid-in capital
289
Retained earnings
-354
Other comprehensive income
-0.25
Shareholders' equity
-64.9
Minority interests
-3.91
Total equity
-68.8
Total liabilities and equity
15.4
Cash flow statement
FY2025
Net income
-18.7
Depreciation and amortization
0.02
Stock-based compensation
2.35
Change in receivables
-1.44
Change in inventory
-0.14
Change in payables
2.79
Cash from operations
-21.2
Capital expenditures
-0.14
Cash from investing
-0.23
Debt repaid
-0.02
Cash from financing
22
Net change in cash
0.28
Free cash flow
-21.4
Interest paid
0.39
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $1.04 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
13.1%
Gross profit / revenue.
Operating margin
-29.7%
Operating income / revenue.
EBITDA margin
-29.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-32.7%
Pre-tax income / revenue.
Net margin
-53.2%
Net income / revenue.
FCF margin
-37.4%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-37.1%
Cash from operations / revenue.
Return on assets (ROA)
-197.6%
Net income / average total assets.
R&D / revenue
3.2%
Research and development expense / revenue.
Stock-based pay / revenue
4.1%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.3%
Capital expenditures / revenue.
D&A / revenue
0.0%
Depreciation and amortization / revenue.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.48x
Current assets / current liabilities.
Quick ratio
0.13x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.04x
(Cash + short-term investments) / current liabilities.
Debt / assets
76.1%
Total debt / total assets.
Liabilities / assets
547.5%
Total liabilities / total assets.
Net debt
$10.3M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$3.14
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$3.14
Net income per basic share, as reported (split-adjusted).
Revenue per share
$5.91
Revenue / diluted weighted shares.
FCF per share
-$2.21
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.19
Cash from operations / diluted weighted shares.
Book value per share
-$6.71
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.14x
Market cap / revenue.
EV/Sales
0.32x
Enterprise value / revenue.
FCF yield
-275.7%
Free cash flow / market cap.
Earnings yield
-392.1%
Net income / market cap (the inverse of P/E).
What was POMDOCTOR Ltd's revenue in fiscal 2025?
POMDOCTOR Ltd reported revenue of $57.2M for fiscal 2025.
Was POMDOCTOR Ltd profitable in fiscal 2025?
No. It reported a net loss of $30.4M.
How much free cash flow did POMDOCTOR Ltd generate in fiscal 2025?
Cash from operations of $21.2M minus capital expenditures of $144.1K left free cash flow of -$21.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.